Structure via PubChem · Public domain (PubChem)
fabomotizole
Sign in to savethumb|Afobazole from Russia
Chemical data
- Formula
- C15H21N3O2S
- Molecular weight
- 307.4 g/mol
- IUPAC name
- 4-[2-[(6-ethoxy-1H-benzimidazol-2-yl)sulfanyl]ethyl]morpholine
- SMILES
- CCOC1=CC2=C(C=C1)N=C(N2)SCCN3CCOCC3
- InChIKey
- WWNUCVSRRUDYPP-UHFFFAOYSA-N
- XLogP
- 2.3
- Polar surface area
- 75.7 Ų
- H-bond donors
- 1
- H-bond acceptors
- 5
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Phase 3
- Molecule type
- Small molecule
- Indications
- anxiety
via ChEMBL · EBI
Wikidata facts
- Subclass of
- heterocyclic compound
- Has part
- carbon
- Mass
- 307.135
Show 4 more facts
- defined daily dose
- 30
- canonical SMILES
- CCOC1=CC2=C(C=C1)N=C(N2)SCCN3CCOCC3
- chemical formula
- C₁₅H₂₁N₃O₂S
- Commons category
- Fabomotizole
Sources (3)
via Wikidata · CC0
~1 min read
Encyclopedic overview
2 sectionsContents
- See also
- References
thumb|Afobazole from Russia
Fabomotizole (INN; brand name Afobazole) is an anxiolytic drug launched in Russia in the early 2000s. It produces anxiolytic and neuroprotective effects without any sedative or muscle relaxant actions. Its mechanism of action remains poorly defined however, with GABAergic, NGF- and BDNF-release-promoting, MT1 receptor agonism, MT3 receptor antagonism, and sigma agonism suggested as potential mechanisms. Fabomotizole was shown to inhibit MAO-A reversibly and there might be also some involvement with serotonin receptors. Clinical trials have shown fabomotizole to be well tolerated and reasonably effective for the treatment of anxiety.
Excerpted from Wikipedia’s “fabomotizole” article, available under the CC BY-SA 4.0 licence.